Principal, Global Trading Systems (GTS)
Moderna may be developing the world's most important new product: a coronavirus vaccine.
Bancel has been Moderna's CEO since the company launched in 2010. It is building a new class of medicine around the company's messenger RNA technology.
Headed into 2020, Moderna's first mRNA vaccine was still years from reaching the market. That changed with the pandemic. The Cambridge, Massachusetts-based biotech has ascended into the industry's top ranks this year, despite having no approved drugs or vaccines.
Its platform allows scientists to create experimental vaccines solely from the genetic code of the virus without needing live samples. That speedy approach has led Moderna to be a front-runner in the race for a cure, outpacing some big pharma rivals.
An effective coronavirus vaccine would be a world-changing accomplishment. In the coming months, we’ll know if Moderna's candidate can succeed in late-stage trials.
Bancel sees the real value beyond COVID-19 — in applying Moderna's next-generation technology to a range of diseases.
"It made no sense that this would be a one-drug company,” Bancel tells Business Insider. “It would be either zero or many many dozens."